Anti-SARS-CoV-2 Receptor-Binding Domain Total Antibodies Response in Seropositive and Seronegative Healthcare Workers Undergoing COVID-19 mRNA BNT162b2 Vaccination
Background: This study monitored total anti-SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) RBD (receptor-binding domain) antibodies levels in a large population of healthcare workers undergoing mRNA COVID-19 vaccination. Methods. The study population consisted of employees of Pederzoli...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-05-01
|
| Series: | Diagnostics |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2075-4418/11/5/832 |
| _version_ | 1827693350451412992 |
|---|---|
| author | Gian Luca Salvagno Brandon M. Henry Giovanni di Piazza Laura Pighi Simone De Nitto Damiano Bragantini Gian Luca Gianfilippi Giuseppe Lippi |
| author_facet | Gian Luca Salvagno Brandon M. Henry Giovanni di Piazza Laura Pighi Simone De Nitto Damiano Bragantini Gian Luca Gianfilippi Giuseppe Lippi |
| author_sort | Gian Luca Salvagno |
| collection | DOAJ |
| description | Background: This study monitored total anti-SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) RBD (receptor-binding domain) antibodies levels in a large population of healthcare workers undergoing mRNA COVID-19 vaccination. Methods. The study population consisted of employees of Pederzoli Hospital of Peschiera del Garda (Verona, Italy), who underwent voluntary vaccination with two doses of COVID-19 mRNA BNT162b2 (Comirnaty; Pfizer Inc). Venous blood was drawn immediately before the first vaccine dose, as well as 21 days (immediately before second vaccine dose) and 50 days afterwards. Humoral response was assessed with Roche Elecsys Anti-SARS-CoV-2 S total antibodies, on Roche Cobas 6000 (Roche Diagnostics). Results: The final study population consisted of 925 subjects (mean age, 44 ± 13 years; 457 women), 206 (22.3%) anti-SARS-CoV-2 baseline seropositive. The increase of total anti-SARS-CoV-2 RBD antibodies levels 21 days after the first vaccine dose was ~3 orders of magnitude higher in seropositive than in seronegative individuals (11782 vs. 42 U/mL; <i>p</i> < 0.001). Total anti-SARS-CoV-2 RBD antibodies levels further increased by over 30-fold after the second vaccine dose in baseline seronegative subjects, while such increase was only ~1.3-fold in baseline seropositive subjects. In multivariate analysis, total anti-SARS-CoV-2 RBD antibodies level was inversely associated with age after both vaccine doses and male sex after the second vaccine dose in baseline seronegative subjects, while baseline antibodies value significantly predicted immune response after both vaccine doses in baseline seropositive recipients. Conclusion: Significant difference exists in post-mRNA COVID-19 vaccine immune response in baseline seronegative and seropositive subjects, which seems dependent on age and sex in seronegative subjects, as well as on baseline anti-SARS-CoV-2 antibodies level in seropositive patients. |
| first_indexed | 2024-03-10T11:42:25Z |
| format | Article |
| id | doaj.art-7121b1d0104b40b7b7662af41038ca39 |
| institution | Directory Open Access Journal |
| issn | 2075-4418 |
| language | English |
| last_indexed | 2024-03-10T11:42:25Z |
| publishDate | 2021-05-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Diagnostics |
| spelling | doaj.art-7121b1d0104b40b7b7662af41038ca392023-11-21T18:23:07ZengMDPI AGDiagnostics2075-44182021-05-0111583210.3390/diagnostics11050832Anti-SARS-CoV-2 Receptor-Binding Domain Total Antibodies Response in Seropositive and Seronegative Healthcare Workers Undergoing COVID-19 mRNA BNT162b2 VaccinationGian Luca Salvagno0Brandon M. Henry1Giovanni di Piazza2Laura Pighi3Simone De Nitto4Damiano Bragantini5Gian Luca Gianfilippi6Giuseppe Lippi7Section of Clinical Biochemistry, University of Verona, 37126 Verona, ItalyCincinnati Children’s Hospital Medical Center, The Heart Institute, Cincinnati, OH 45229, USAMedical Direction, Pederzoli Hospital, 37019 Peschiera del Garda, ItalySection of Clinical Biochemistry, University of Verona, 37126 Verona, ItalySection of Clinical Biochemistry, University of Verona, 37126 Verona, ItalyInfectious Diseases Unit, Pederzoli Hospital, 37019 Peschiera del Garda, ItalyMedical Direction, Pederzoli Hospital, 37019 Peschiera del Garda, ItalySection of Clinical Biochemistry, University of Verona, 37126 Verona, ItalyBackground: This study monitored total anti-SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) RBD (receptor-binding domain) antibodies levels in a large population of healthcare workers undergoing mRNA COVID-19 vaccination. Methods. The study population consisted of employees of Pederzoli Hospital of Peschiera del Garda (Verona, Italy), who underwent voluntary vaccination with two doses of COVID-19 mRNA BNT162b2 (Comirnaty; Pfizer Inc). Venous blood was drawn immediately before the first vaccine dose, as well as 21 days (immediately before second vaccine dose) and 50 days afterwards. Humoral response was assessed with Roche Elecsys Anti-SARS-CoV-2 S total antibodies, on Roche Cobas 6000 (Roche Diagnostics). Results: The final study population consisted of 925 subjects (mean age, 44 ± 13 years; 457 women), 206 (22.3%) anti-SARS-CoV-2 baseline seropositive. The increase of total anti-SARS-CoV-2 RBD antibodies levels 21 days after the first vaccine dose was ~3 orders of magnitude higher in seropositive than in seronegative individuals (11782 vs. 42 U/mL; <i>p</i> < 0.001). Total anti-SARS-CoV-2 RBD antibodies levels further increased by over 30-fold after the second vaccine dose in baseline seronegative subjects, while such increase was only ~1.3-fold in baseline seropositive subjects. In multivariate analysis, total anti-SARS-CoV-2 RBD antibodies level was inversely associated with age after both vaccine doses and male sex after the second vaccine dose in baseline seronegative subjects, while baseline antibodies value significantly predicted immune response after both vaccine doses in baseline seropositive recipients. Conclusion: Significant difference exists in post-mRNA COVID-19 vaccine immune response in baseline seronegative and seropositive subjects, which seems dependent on age and sex in seronegative subjects, as well as on baseline anti-SARS-CoV-2 antibodies level in seropositive patients.https://www.mdpi.com/2075-4418/11/5/832COVID-19SARS-CoV-2vaccineimmune responseantibodies |
| spellingShingle | Gian Luca Salvagno Brandon M. Henry Giovanni di Piazza Laura Pighi Simone De Nitto Damiano Bragantini Gian Luca Gianfilippi Giuseppe Lippi Anti-SARS-CoV-2 Receptor-Binding Domain Total Antibodies Response in Seropositive and Seronegative Healthcare Workers Undergoing COVID-19 mRNA BNT162b2 Vaccination Diagnostics COVID-19 SARS-CoV-2 vaccine immune response antibodies |
| title | Anti-SARS-CoV-2 Receptor-Binding Domain Total Antibodies Response in Seropositive and Seronegative Healthcare Workers Undergoing COVID-19 mRNA BNT162b2 Vaccination |
| title_full | Anti-SARS-CoV-2 Receptor-Binding Domain Total Antibodies Response in Seropositive and Seronegative Healthcare Workers Undergoing COVID-19 mRNA BNT162b2 Vaccination |
| title_fullStr | Anti-SARS-CoV-2 Receptor-Binding Domain Total Antibodies Response in Seropositive and Seronegative Healthcare Workers Undergoing COVID-19 mRNA BNT162b2 Vaccination |
| title_full_unstemmed | Anti-SARS-CoV-2 Receptor-Binding Domain Total Antibodies Response in Seropositive and Seronegative Healthcare Workers Undergoing COVID-19 mRNA BNT162b2 Vaccination |
| title_short | Anti-SARS-CoV-2 Receptor-Binding Domain Total Antibodies Response in Seropositive and Seronegative Healthcare Workers Undergoing COVID-19 mRNA BNT162b2 Vaccination |
| title_sort | anti sars cov 2 receptor binding domain total antibodies response in seropositive and seronegative healthcare workers undergoing covid 19 mrna bnt162b2 vaccination |
| topic | COVID-19 SARS-CoV-2 vaccine immune response antibodies |
| url | https://www.mdpi.com/2075-4418/11/5/832 |
| work_keys_str_mv | AT gianlucasalvagno antisarscov2receptorbindingdomaintotalantibodiesresponseinseropositiveandseronegativehealthcareworkersundergoingcovid19mrnabnt162b2vaccination AT brandonmhenry antisarscov2receptorbindingdomaintotalantibodiesresponseinseropositiveandseronegativehealthcareworkersundergoingcovid19mrnabnt162b2vaccination AT giovannidipiazza antisarscov2receptorbindingdomaintotalantibodiesresponseinseropositiveandseronegativehealthcareworkersundergoingcovid19mrnabnt162b2vaccination AT laurapighi antisarscov2receptorbindingdomaintotalantibodiesresponseinseropositiveandseronegativehealthcareworkersundergoingcovid19mrnabnt162b2vaccination AT simonedenitto antisarscov2receptorbindingdomaintotalantibodiesresponseinseropositiveandseronegativehealthcareworkersundergoingcovid19mrnabnt162b2vaccination AT damianobragantini antisarscov2receptorbindingdomaintotalantibodiesresponseinseropositiveandseronegativehealthcareworkersundergoingcovid19mrnabnt162b2vaccination AT gianlucagianfilippi antisarscov2receptorbindingdomaintotalantibodiesresponseinseropositiveandseronegativehealthcareworkersundergoingcovid19mrnabnt162b2vaccination AT giuseppelippi antisarscov2receptorbindingdomaintotalantibodiesresponseinseropositiveandseronegativehealthcareworkersundergoingcovid19mrnabnt162b2vaccination |